CAR-T therapy yields long-term survival for patients with lymphoma

by | Dec 11, 2025 | Health

Spread the love
A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved CAR-T cell therapies offers long-term survival and potential cures for adult patients with relapsed or refractory large B-cell lymphoma, even years after treatment.

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments